News test - Prioritis

October 20, 2017
ISPOR 20th Annual European Congress
News
October 23, 2017
Singapore’s HTA decisions in Prismaccess and Evalumade
News
November 30, 2017
Peru’s HTA Agency reports in Prismaccess & Evalumade platforms
News
January 09, 2018
PRIORITIS heads a market access training at Paris-Dauphine University
News
January 31, 2018
RWD and RWE will play an increasing role in health care decisions
News
February 09, 2018
Annual report from French Economic Committee (CEPS)
News
February 14, 2018
2018, innovations and new economic models
News
February 19, 2018
Prismaccess’ data in an international study in oncology
News
February 26, 2018
Spain, a new financing model for high economic-impact medicines
News
March 13, 2018
Prioritis at Pharma Pricing and Market Access congress London
News
May 14, 2018
Prioritis at ISPOR Baltimore
News
May 30, 2018
FDA wishes faster approval for gene therapies
News
July 05, 2018
Drug Reimbursement and Pricing Policy in Taiwan
News
October 09, 2018
Japanese decisions in Prismaccess and Evalumade
News
November 05, 2018
Prioritis at ISPOR Barcelona – Stand 201
News
February 18, 2019
Prioritis at Pricing & Market Access Amsterdam
News
October 22, 2019
Prioritis at ISPOR Copenhagen stand C2-037
News
February 12, 2020
EMA after Brexit? Prioritis continues to monitor the changes
News
January 08, 2021
Best wishes from Prioritis
News
January 14, 2021
New routes to marketing approval in Great Britain
News
January 20, 2021
Innovative CAR-T cell therapy set to be reimbursed by NICE
News
February 10, 2021
Cost-effectiveness and budget impact to be included in new IPTs
News
February 25, 2021
Japan’s First Pricing Reform Since 2013, expected in April 2021
News
March 19, 2021
UK Cancer Drugs Fund to be expanded for non-cancer therapies
News
October 06, 2021
New indications in oncology not easily accessible to French patients
News
July 11, 2022
China available as an optional add-on for Prismaccess
News